A clinical trial assessing Rapastinel
Latest Information Update: 23 Jun 2025
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Expanded access; Therapeutic Use
Most Recent Events
- 27 May 2025 According to Syndeio Biosciences media release, Gate Neurosciences name changed to Syndeio Biosciences.
- 04 Oct 2022 New trial record
- 29 Sep 2022 According to Gate Neurosciences, avancement of Rapastinel (GLYX-13) into this nvestigator led study in collaboration with multiple leading research hospitals, under the FDAs Expanded Access Program, beginning in 2023